2619847-12-8
Chemical Structure
TSL2109
- CAS No.: 2619847-12-8
- Formula:C28H33FN8OS
- Molecular Weight:548.68
InChIKey: QXLHPZGOJNRMDZ-UHFFFAOYSA-N
SMILES: FC1=C(C2=CC=C3N=C(SC3=C2)N(CC)CC)N=C(NC4=NC=C(C=C4)C(N5CCN(CC5)C(C)C)=O)N=C1
Biological Activity:
TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC50 value of 22 nM for DYRK2. TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide (HY-70002) resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TSL2109 | TSL2109 is an orally active and selective DYRK2 and CDK4/6 inhibitor with an IC50 value of 22 nM for DYRK2. TSL2109 exhibits high kinase selectivity over 93%. TSL2109 arrests cell cycle and induces apoptosis in virto. TSL2109 effectively overcomes Enzalutamide (HY-70002) resistance by suppressing tumor growth in vivo and virto. TSL2109 also shows CDK4/6 inhibitor resistance.TSL2109 demonstrates safety profile. TSL2109 can be used for prostate cancer research and breast cancer. |
|||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
